抗菌肽 LL-37 促进肝癌细胞的 EMT、迁移和转移：体外和小鼠模型研究。
Cathelicidin LL-37 promotes EMT, migration and metastasis of hepatocellular carcinoma cells in vitro and mouse model.
机构信息
Jiangsu Province Key Laboratory for Molecular and Medical Biotechnology, Life Sciences College, Nanjing Normal University, Nanjing, Jiangsu, China.
出版信息
Cell Adh Migr. 2023 Dec;17(1):20-34. doi: 10.1080/19336918.2023.2168231.
The effect of cathelicidin hCAP18/LL-37 in hepatocellular carcinoma (HCC) metastasis remains unclear. Here, we confirmed that LL-37 expression enhanced endothelial-mesenchymal transition (EMT), migration and invasion in HCC cells. And the HER2/EGFR-MAPK/ERK signal participated in the process above. More frequent lung metastases were observed in an LL-37-overexpressing hematogenous metastasis model. Interestingly, 1,25(OH)D together with si-LL-37 significantly enhanced 1,25(OH)D-induced inhibition of migration and invasion in PLC/PRF-5 cells, and also enhanced reversion of the EMT process. Therefore, LL-37 is involved in HCC metastases, and may act as an important factor to attenuate the inhibitory activity of 1,25(OH)D on HCC metastasis. Targeting hCAP18/LL-37 may offer a potential strategy to improve the anticancer activity of 1,25(OH)D in HCC therapy.
cathelicidin hCAP18/LL-37 在肝细胞癌 (HCC) 转移中的作用尚不清楚。在这里，我们证实 LL-37 表达增强了 HCC 细胞中的内皮-间充质转化 (EMT)、迁移和侵袭。HER2/EGFR-MAPK/ERK 信号参与了这一过程。在一个过表达 LL-37 的血源性转移模型中观察到更频繁的肺转移。有趣的是，1,25(OH)D 与 si-LL-37 一起显著增强了 1,25(OH)D 诱导的 PLC/PRF-5 细胞迁移和侵袭抑制，并且还增强了 EMT 过程的逆转。因此，LL-37 参与 HCC 转移，并且可能作为减弱 1,25(OH)D 对 HCC 转移抑制活性的重要因素。靶向 hCAP18/LL-37 可能为提高 1,25(OH)D 在 HCC 治疗中的抗癌活性提供一种潜在策略。
Zotero 插件